Longitudinal tracking of Ig and non-Ig VAFs in FFPE tissue DNA and cfDNA. (A-C) Representative patient cases showing VAF dynamics for both Ig and non-Ig somatic variants in FFPE tumor tissue (shaded region) and corresponding cfDNA at baseline, during treatment, including interim, and EOT time points: patient 1199 (A); patient 1201 (B); and patient 1303 (C). Ig-related variants (green) complement non-Ig markers (red), such as BCL2, MYC, MYD88, or TP53, at generally lower VAFs and reflect the clinical treatment response. Locally weighted smoothing (LOWESS) was used for nonparametric curve regression. For simplicity, a 95% confidence interval at each time point is shown for non-Ig markers only. C, cycle; FU, follow-up; L, treatment line.
Figure 2.

Longitudinal tracking of Ig and non-Ig VAFs in FFPE tissue DNA and cfDNA. (A-C) Representative patient cases showing VAF dynamics for both Ig and non-Ig somatic variants in FFPE tumor tissue (shaded region) and corresponding cfDNA at baseline, during treatment, including interim, and EOT time points: patient 1199 (A); patient 1201 (B); and patient 1303 (C). Ig-related variants (green) complement non-Ig markers (red), such as BCL2, MYC, MYD88, or TP53, at generally lower VAFs and reflect the clinical treatment response. Locally weighted smoothing (LOWESS) was used for nonparametric curve regression. For simplicity, a 95% confidence interval at each time point is shown for non-Ig markers only. C, cycle; FU, follow-up; L, treatment line.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal